Targeting the TLK1/NEK1 DDR axis with Thioridazine suppresses outgrowth of androgen independent prostate tumors

Standard therapy for advanced Prostate Cancer (PCa) consists of antiandrogens, which provide respite from disease progression, but ultimately fail resulting in the incurable phase of the disease: mCRPC. Targeting PCa cells before their progression to mCRPC would greatly improve the outcome. Combinat...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Vibha, Jaiswal, Praveen Kumar, Ghosh, Ishita, Koul, Hari K., Yu, Xiuping, De Benedetti, Arrigo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Molecular Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617729/
https://www.ncbi.nlm.nih.gov/pubmed/30737777
http://dx.doi.org/10.1002/ijc.32200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617729/
https://www.ncbi.nlm.nih.gov/pubmed/30737777
http://dx.doi.org/10.1002/ijc.32200

Ejemplares similares